MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 50.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.09M |
| Shares Out | 10.95M |
| EPS (ttm) | -1.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,143 |
| Open | 4.81 |
| Previous Close | 4.73 |
| Day's Range | 4.48 - 4.73 |
| 52-Week Range | 3.10 - 9.64 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 10.84 (+137.2%) |
| Earnings Date | n/a |
About MAIA
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MAIA stock is "Buy." The 12-month stock price forecast is $10.84, which is an increase of 137.20% from the latest price.
News
MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today the advancement of its Telomere-Targeting Molecule Program (“Project T3”). MAIA is designing and evaluating m...
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences a...
MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) today announced that it completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food...
MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), announced today that regulatory authorities in three European countries, Hungary, Poland, and Bulgar...
MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology...
MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ann...
MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today repo...
MAIA Biotechnology: Invitation to The ThinkEquity Conference
Chicago, Illinois--(Newsfile Corp. - October 12, 2022) - MAIA Biotechnology (NYSE: MAIA), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, wil...
MAIA Biotechnology to Participate in ThinkEquity Conference
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology d...
MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology d...
MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology d...
MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today annou...
MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), today announced that it has been...
MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today repo...
MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology d...
MAIA Biotechnology Announces Closing of Initial Public Offering
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today anno...
Why Is MAIA Biotechnology (MAIA) Stock Soaring 15% Higher Today?
MAIA Biotechnology (NYSE: MAIA), which began trading on Thursday following its initial public offering, is climbing sharply this morning. In mid-morning trading, MAIA stock jumped 15% to $6.66.
MAIA Biotechnology Announces Pricing of Initial Public Offering
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today anno...